19:05 , Aug 10, 2018 |  BC Week In Review  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions, noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower list...
20:46 , Aug 7, 2018 |  BC Extra  |  Company News

Zepatier lands co-exclusive status on Express Scripts 2019 formulary

Express Scripts Holding Co. (NASDAQ:ESRX) announced its 2019 National Preferred Formulary Exclusions, noting that the exclusions were driven not only by the size of the rebate as in years past, but also by lower list...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Tenofovir alafenamide fumarate: Phase III data

Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif.   Product: Tenofovir alafenamide fumarate (TAF)/elvitegravir/cobicistat/emtricitabine (formerly GS-7340/elvitegravir/cobicistat/emtricitabine)   Business: Infectious   Molecular target: NA   Description: Co-formulated single-tablet regimen of tenofovir alafenamide fumarate (TAF), a prodrug of tenofovir, a...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and commercial launches...
08:00 , Nov 3, 2014 |  BioCentury  |  Finance

Shooting F-stars

F-star Alpha Ltd.'s deal with Bristol-Myers Squibb Co. (NYSE:BMY) last week is the first validation of the parent platform company's strategy of speeding returns by packaging assets into corporations for buyer convenience and seller financial...
07:00 , Jul 28, 2014 |  BioCentury  |  Finance

Staying the course with half a billion

Sofinnova Ventures is sticking with what works for its second life sciences-only fund, which the firm closed last week at $500 million. The fund, the firm's ninth overall, was oversubscribed and was originally targeting $425 million....
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Venture hots up

Private biotechs have raised $3.1 billion since the start of the year, double the $1.5 billion raised in the same period last year. At least one investor contacted by BioCentury expects the pace to continue...